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148S ABSTRACTS FROM IXth WORLD CONGRESS ON JVF AND ALTERNATE ASSISTED REPRODUCTION
Severe ovarian fcyperstinmlstion despite prophylactic albumin admlnbtration 
at the lime of oocyte retrieval in * cycle of control!«! ovarian
bypentfcmulatio*.
T. MuVhajee, A.B. Coppermaa. L. GiunTeld, B. Sandler, M.Drewa, M. Bussilo
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology, 
Mount Situi Medical Center, New York, NY
Objective: To report Ibe occurence of two caua of «evert ovarian bypentimulation 
(OHSS) despite ihe administration of 30 grams intiavwtouj albumin at Ox time of 
oocyte retrieval. Two previous report* involving 52 patients did not describe « »ingle 
ewe of OHSS in patient« receiving projihylactic intra venom albumin. We describe 
the expemnce at ottf insti luti on where two paiiarti were hospitalized with severo 
OHSS despite receiving propbyl actio albumin therapy.
Design: Two leve consecutive patients undergoing a cycle of controlled ovarian 
hypentimitition for IVF with peak, estradiol greater than 4500 pg/ml recicvcd 30 
¿ran» intravenous albumin (200 cc of i 25% albumin solution) al ihe time of oocyte 
retreivaL Two patients developed OHSS despite prophlyacUc albumin 
vimini strati on.
Scttlnf : The Division of Reproductive Efldocriftology al the ML Sinai Medical 
Center, New Voric.
Intenrentiom; 50 gram intravoxxu albomia was. adminutered over 30 nninuUs at 
the time of oocyte rrtrieval.
Mala oairo«e measure: Outcome measure» included the accumulation of 
interstitial fluid Mich as ucitea, pleural e {futi cm, and generalized edema. The other 
outcome variable« included degree of honoooncentralioo, renal inaufficency, and 
throtnlxtfk: complkaliom-
Two patitici developed severe OHSS, requiring hospitalization, despile 
administration of intnveooui albumin. The peak estradiols of the two patients "wer* 
4993 and 7180 pg/ml, Both patients cvideooed abort«* of breath, pleural efTurion, 
ovanan cnlar^ emert, aacttas, and hennooonoenbatioa This ii the first report to our 
knowledge, where administration of prophylactic albumin hai failed to prevent severe 
OHSS. ft is important to report negative m  well as positive outcome« to evaluate ihe 
um oTaJhomin as a prophylactic agent The true eflkacy ofthù agent needs to be 
evaluated in a prospectiverandomized fashion.
PP-101 PP-103
A COMPARISON OF RECOMBINANT HUMAN FSH (PUREGON) AND 
HMGINIVF CYCLES
IJM DuHkere1. JMG Hollanders’ , CJCM Hamilton1, WNP Willemsen1, 
CMG Thomas1, HJ Out2, HJT Coelingh Bennink2
1 University Hospital Nijmegen, 2NV Organon, Oss; Netherlands.
The effect of intramuscular (IM) recombinant human FSH {Puregon) 
administration on follicular development and hormonal profiles in IVF 
cycles was investigated in comparison with IM hMG treatment in a ran­
domized study, using a fixed dosing scheme. Thirteen IVF patients 
fulfilling strict selection criteria were included. Seven patients were 
treated with hMG and six patients with Puregon, In both groups in 
combination with GnRH-agonist (buserelin) treatment. 150 IU hMG or 
Puregon were Injected once daily, During the stimulation phase, daily 
blood samples were taken to determine FSH, LH, oestradiol (E2) and 
progesterone concentrations, and vaginal ultrasonography was perfor­
med at least every other day. When the mean diameter of the largest 
follicle was 20 mm and the endometrial thickness was 9 mm, hCG was 
administered, The luteal phase was suppleted by progesterone,
Results:
Median numbers of follicles, FSH and E2 levels at the day of hCG admi­
nistration and numbers of retrieved oocytes are listed in the table,
hMG Puregon
N foil >10 mm 12 17
N foil >15 mm 9 12
FSH mil) 6.6 5.1
E2 (pmol/L) 6100 7550
N oocytes 7 11
Conclusion: Due to the small sample size, the differences were not 
statistically significant However, the results suggest that Puregon is at 
least as potent as hMG.
PP-102
LOW DOSES OF HUMAN MENOPAUSAL GONADOTROPIN
WITH CL 0MI PHENE CITRATE IM IVF PROGRAM 
F.V.Dakhno» V-Y*Syrenkoi A.S.DariJ, T.R.Tikhonirova 
Institute of Reproductive Medicine 
Kievi Ukraine
We conducted 120 cycles Df the controlled superovulation 
(CS0) of 106 wonen selected for IVF program* The mean age 
of women was 30-6 years* The average duration of inferti­
lity» was 7|9 yearsi 35 K Df wonen had a primary inferti­
lity and 45 % had a secondary infertility. The tubal fac- 
tor was the nain reason of IVF treatment (SB 14 }{)• CS0 
was with combination of cloaiphene citrate Cl00 mg/d fron 
the 2-3 day of cycle during 5 days) with hMG < Pergonal* 
Sercma) given -fro» the 2-3 day of cycle every second day 
2-3 ampules i <«• The naan number of ampules used per pa~ 
tient was B>3 which is auch lower than the mean dose in 
accordance with the majority of the European IVF groups 
reports. The huaan chorionic gonadotropin (Profasli Sero- 
no) was usually administered according to generally acce­
pted methods 35 hours before the ultrasonical ly-guided 
oocyte collection. The mean number of follicles was 6i87 
per 1 cycle and 3«90 oocytes were retrieved. Using visual 
control ws determined that 73 J( of eggs were nature* 3»1 
- immaturei 9i4 5fi were with the atretic signs and 16»5 ¡( 
were degenerated. Fertilization rate was 64»8 %• The do­
nor's embryo transfer was made to 9 patients and 11 pa- 
tients were taken off the program because of the absence 
Df egg's cleavage. The luteal phase was supposted by the 
administration of 1dm hCG doses- The pregnancy rate was 
151& % and 4 of wonen gave a birth to healthy children 
(in one case the twins were born)* In 1 case a combinati­
on of uterine and tube pregnancy took place ( the tube 
amputation and artificial abortion was made because of 
nterine bleeding) and spontanious abortion took place in 
J2 cases* The received results can't be considered as suc­
cessive* We see the possibility Df our work results heih- 
tening in the improvement of ovary stimulation protocoles 
taking into account the uterine receptivity readiness for 
Bnbryo implantation« optimization of luteal phase and ear­
ly pregnancy supplement and also in more thorough selecti­
on of patients for IVF program« Nevertheless) we should 
acknoledge that the excessive pragmatism in this question 
will inevitably cone into conflict with a humanity and 
wish to help.
PP-104
DOES INTENSIVE PROPHYLAXIS OF SEVERE OHSS AFFECT 
THE PREGNANCY RATE OF IN VITRO FERTILIZATION AND 
EMBRYO TRANSFER?
J, Fukuda. H. Kodama, H. Karube, Y. Shimizu, T. Tanaka,
Dept, of Ob/Gyn, Akita University School of Medicine,
Akita, Japan,
Ovarian hyperstimulation syndrome (OHSS) is a severe iatrogenic 
complication of ovulation inductions in otherwise healthy young 
women. The aim of this study was to evaluate whether intensive 
prevention of this complication affected on the pregnancy rate of in 
vitro fertilization and embryo transfer (IVF-ET). In order to reduce 
the incidence of this complication, we introduced several prophylactic 
strategies since October 1992. These strategies included (a) individual 
adjustment of a daily dose of hMG to young patients, (b) one day 
earlier injection of hCG when a large number of growing follicles 
was observed,.(c) cancellation of hCG administration in the patients 
with a remarkably large number of growing follicles, (d) use of pure 
FSH, instead of hMG, in patients with polycystic ovarian syndrome. 
The results of IVF-ET before and after the introduction of these 
strategies were compared (864 cycles during the period from October 
1988 to September 1992, Phase I, versus 649 cycles from October 
1992 to July 1994, Phase II). Incidence of severe OHSS was 
remarkably decreased from Phase 1 to Phase II (3.4 versus 0.6%, 
p<0.001), Although the number of recovered oocytes in the Phase II 
was significantly lower than that in the Phase I (6.7±4.6 versus 
7.6+53, pcO.OOl, mean ± SD ), pregnancy rates did not differ 
between the two Phases (23.3 versus 24.0%). We concluded that
intensive prophylaxis of OHSS did not affect pregnancy rate of IVF- 
ET.
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